Home › Funds › Vestal Point Capital, LP › GMED
Vestal Point Capital, LP position in GMED
GLOBUS MED INC · Health Care
Vestal Point Capital, LP reported holding 850,000 shares of GMED (GLOBUS MED INC) in its Q2 2026 13F filing — a position valued at US$67.2M, representing 1.57% of its reported portfolio and ranking #22 among its reported holdings. Vestal Point Capital, LP has disclosed GMED holdings in 10 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Vestal Point Capital, LP's GMED position evolved
Vestal Point Capital, LP first disclosed a stake in GMED in Q4 2023 at 800,000 shares (US$42.6M). The position peaked in Q4 2025 at 1,275,000 shares, worth US$111.3M. Across 10 filings, Vestal Point Capital, LP increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 850,000 shares valued at US$67.2M — an increase of 239,480 shares quarter over quarter.. Notable position changes include a 150% increase in Q2 2025 (shares fell 3% over the following quarter), a 150% increase in Q3 2025 (shares rose 52% over the following quarter), a 52% trim in Q1 2026 (shares fell 8% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 800.00K | $42.63M | New |
| Q1 2024 | 1.00M | $53.64M | Add |
| Q2 2024 | 900.00K | $61.64M | Reduce |
| Q4 2024 | 325.00K | $26.88M | New |
| Q1 2025 | 200.00K | $14.64M | Reduce |
| Q2 2025 | 500.00K | $29.51M | Add |
| Q3 2025 | 1.25M | $71.59M | Add |
| Q4 2025 | 1.27M | $111.32M | Add |
| Q1 2026 | 610.52K | $52.60M | Reduce |
| Q2 2026 | 850.00K | $67.16M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GMED and 13F data
GMED (GLOBUS MED INC) is a Health Care company. 39 other funds we track also report a position in GMED — the largest reported positions include KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC (US$338.1M), Sculptor Capital LP (US$237.0M), Boston Trust Walden Corp (US$124.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GMED
- KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC 4.28M sh · $338.14M · Q2 2026
- Sculptor Capital LP 3.00M sh · $237.03M · Q2 2026
- Boston Trust Walden Corp 1.57M sh · $124.31M · Q2 2026
- GW&K Investment Management, LLC 1.45M sh · $114.82M · Q2 2026
- GENEVA CAPITAL MANAGEMENT LLC 1.42M sh · $111.96M · Q2 2026
- Madison Avenue Partners, LP 935.22K sh · $73.89M · Q2 2026
- ANTIPODES PARTNERS Ltd 905.98K sh · $71.58M · Q2 2026
- PARADIGM CAPITAL MANAGEMENT INC/NY 886.50K sh · $70.04M · Q2 2026
More on Vestal Point Capital, LP
FAQ
How long has Vestal Point Capital, LP held GMED?
Vestal Point Capital, LP has disclosed GMED holdings in 10 of the last 11 reported quarters, going back to Q4 2023.
What is Vestal Point Capital, LP's current position in GMED?
As of Q2 2026, Vestal Point Capital, LP holds 850.00K shares of GMED (GLOBUS MED INC), valued at $67.16M, representing 1.57% of its reported portfolio and ranking #22.
Has Vestal Point Capital, LP been buying or selling GMED?
In the latest 13F filing (Q2 2026), Vestal Point Capital, LP increased its position in GMED. The position peaked in Q4 2025 at 1.27M shares.
Which other funds hold GMED?
Other major institutional holders of GMED include KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC, Sculptor Capital LP, Boston Trust Walden Corp, among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.